Nozawa Masahiro, Uemura Hirotsugu
Department of Urology, Kinki University Faculty of Medicine,377-2 Ohno-higashi, Osaka-sayama, 589-8511, Japan.
Transl Androl Urol. 2013 Dec;2(4):324-7. doi: 10.3978/j.issn.2223-4683.2013.12.03.
The number of molecular targeted agents for advanced renal cell carcinoma (RCC) has gradually increased, but evidence on the optimal order of selection for such agents has not yet caught up with this trend. In addition, timing of switching molecular targeted drugs may also become an important issue for controlling the disease as types of these drugs grow in number. Based on the fact that the efficacy of a rechallenge of the drug previously used suggests the recovery of the sensitivity, a cyclic therapy in which drugs are changed before exacerbation to repeatedly administer several drugs in a rotated manner, may also be an effective sequential therapy.
晚期肾细胞癌（RCC）分子靶向药物的数量逐渐增加，但关于此类药物最佳选择顺序的证据尚未跟上这一趋势。此外，随着这些药物种类的增加，更换分子靶向药物的时机也可能成为控制疾病的一个重要问题。基于之前使用过的药物再次使用时的疗效表明敏感性恢复这一事实，在病情加重前更换药物以轮流方式反复使用几种药物的循环疗法，也可能是一种有效的序贯疗法。
